Ozempic for all? We might be closer than you assume.
Economist Emily Oster joins Michael Smerconish to debate the rising debate over whether or not Medicare and Medicaid ought to cowl GLP-1 weight-loss medicine like Ozempic. With costs dropping and proof mounting that they scale back long-term well being prices, are we nearing some extent the place protection pays for itself?